Loading...
XCNQRAMM
Market cap1mUSD
Dec 23, Last price  
0.02CAD
1D
50.00%
IPO
-97.50%
Name

Ramm Pharma Corp

Chart & Performance

D1W1MN
XCNQ:RAMM chart
P/E
P/S
0.35
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
3.74%
Rev. gr., 5y
-9.50%
Revenues
5m
+29.96%
8,345,6125,610,5725,444,6864,116,0483,897,4155,065,262
Net income
-8m
L-63.16%
-684,582-6,820,452-7,430,597-7,106,804-20,960,045-7,720,911
CFO
-4m
L-25.79%
1,692,772-1,808,545-2,914,528-3,817,674-5,912,994-4,388,023

Profile

RAMM Pharma Corp. engages in the research and development, production, and sale of cannabinoid pharmaceutical formulations, pharmaceuticals, cosmetics, nutraceutical products, and resale of medical supplies products in Canada and internationally. It offers Epifractán, a cannabinoid pharmaceutical drug; XALEX 10, a prescription pharmaceutical formulation for the treatment of refractory epilepsy; and NettaLife, a cannabis-based product for pets. The company was formerly known as MTC Growth Fund-I Inc. and changed its name to RAMM Pharma Corp. in October 2019. RAMM Pharma Corp. was incorporated in 1987 and is based in Toronto, Canada.
IPO date
Nov 08, 2019
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2023‑102022‑102021‑102020‑102019‑102018‑10
Income
Revenues
5,065
29.96%
3,897
-5.31%
Cost of revenue
10,743
10,600
Unusual Expense (Income)
NOPBT
(5,678)
(6,703)
NOPBT Margin
Operating Taxes
10
8
Tax Rate
NOPAT
(5,688)
(6,711)
Net income
(7,721)
-63.16%
(20,960)
194.93%
Dividends
Dividend yield
Proceeds from repurchase of equity
(175)
(221)
BB yield
0.90%
Debt
Debt current
225
230
Long-term debt
585
1,137
Deferred revenue
Other long-term liabilities
Net debt
(4,307)
(10,485)
Cash flow
Cash from operating activities
(4,388)
(5,913)
CAPEX
(62)
(168)
Cash from investing activities
127
(1,152)
Cash from financing activities
(410)
(354)
FCF
(4,170)
(7,721)
Balance
Cash
5,117
9,773
Long term investments
2,079
Excess cash
4,864
11,658
Stockholders' equity
26,418
24,154
Invested Capital
25,006
24,605
ROIC
ROCE
EV
Common stock shares outstanding
121,036
122,773
Price
0.20
-56.99%
Market cap
24,555
-51.31%
EV
14,069
EBITDA
(4,341)
(5,682)
EV/EBITDA
Interest
72
13
Interest/NOPBT